Overview

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune LLC